5. Data availability per treatment group for the outcome 6‐month abstinence.
| Treatment group | SNP or VNTRa | Ethnicity | Number of studies (individuals in homozygous major/heterozygous/homozygous minor) included | Analysis number |
Significant treatment effect Letter indicates which genotype is favoured: ma = genotype group with 1 or more major alleles mi = homozygous minor s = slow NMR n = normal NMR |
P value heterogeneity in genotype comparisons | |
| Active NRT | MaMi | HetMi | |||||
| rs1051730 | NHW | 7 (1352/1025/310) | 57.1 | 0.93 | |||
| NHB | 2 (181/50/6) | 58.1 | 0.98 | ||||
| rs16969968 | NHB | 2 (353/39a) | 59.1 | N/A | |||
| rs588765 | NHW | 3 (286/399/147) | 60.1 | 0.76 | |||
| rs2036527 | NHW | 2 (369/447/132) | 61.1 | 0.79 | |||
| NHB | 2 (232/159a) | 62.1 | N/A | ||||
| DRD4 (exon 3 48 bp) | NHW | 3 (798/253/68) | 63.1 | 0.74 | |||
| SLC6A4 (Promoter) | NHW | 2 (277/465/184) | 64.1 | 0.62 | |||
| Normal vs slow | |||||||
| NMR | NHW and NHB | 2 (400/318) | 65.1 | s | N/A | ||
| Bupropion | |||||||
| rs1051730 | NHW | 4 (220/294/96) | 66.1 | 0.82 | |||
| NHB | 2 (43/20a) | 67.1 | N/A | ||||
| rs16969968 | NHB | 2 (261/33a) | 69.1 | N/A | |||
| rs588765 | NHW | 4 (195/292/109) | 70.1 | 0.80 | |||
| rs2036527 | NHW | 2 (143/204/65) | 71.1 | 0.87 | |||
| NHB | 3 (187/144a) | 72.1 | N/A | ||||
| rs3733829 | NHW | 2 (146/116/45) | 73.1 | 0.65 | |||
| Varenicline | |||||||
| rs16969968 | NHW | 2 (269/349/89) | 83.1 | 0.81 | |||
| rs588765 | NHW | 2 (234/345/120) | 84.1 | 0.90 | |||
| Placebo | |||||||
| rs1051730 | NHW | 6 (377/441/156) | 101.1 | 0.54 | |||
| NHB | 2 (49/14a) | 102.1 | N/A | ||||
| rs16969968 | NHW | 2 (132/181/30) | 103.1 | 0.63 | |||
| NHB | 3 (519/65a) | 104.1 | N/A | ||||
| rs588765 | NHW | 5 (253/340/130) | 105.1 | 0.92 | |||
| NHB | 2 (275/291a) | 106.1 | N/A | ||||
| rs2036527 | NHW | 2 (117/166/43) | 107.1 | 0.81 | |||
| NHB | 4 (373/256a) | 108.1 | N/A | ||||
| DRD4 (exon 3 48 bp) | NHW | 3 (361/186/26) | 109.1 | 0.44 | |||
| rs3733829 | NHW | 2 (122/102/40) | 110.1 | 0.60 | |||
| SLC6A4 (Promoter) | NHW | 2 (128/23a) | 119.1 | N/A | |||
| Normal vs slow | |||||||
| NMR | NHW and NHB | 2 (389/310) | 120.1 | N/A | |||
HetMi: heterozygous vs homozygous minor; MaMi: homozygous major vs homozygous minor; NHB: non‐Hispanic black or African American; NHW: non‐Hispanic white; NMR: nicotine metabolite ratio; NRT: nicotine replacement therapy; NS: normal NMR vs slow NMR; SNP: single‐nucleotide polymorphism; VNTR: variable number tandem repeat.
aHeterozygous and homozygous minor combined.